AzTrials
AzTrials

Readmission, HospitalPhase 2NCT00332514

Post-Discharge Follow-Up Phone Call by a Pharmacist and Impact on Patient Care

A Phase 2 study testing telephone call by a pharmacist in people with Readmission, Hospital, run by Boston Medical Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes. Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topics. They are: 1. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Readmission, Hospital
What is being tested?
telephone call by a pharmacist
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteUnited States
Study dates
Mar 2004to Jan 2008
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • admission to Internal Medicine Service on the Menino Pavilion, either Firm A or B at Boston Medical Center located in Boston, MA
  • age greater than or equal to 18 years
  • discharge to home from the inpatient General Medical Service
  • English-speaking or lives with English-speaking person
  • access to a working phone

Who cannot join

  • admission to any other service at Boston Medical Center located in Boston, MA besides Internal Medicine Firms A or B
  • age less than 18 years
  • discharge to site other than home
  • non-English-speaking or does not live with an English-speaking person
  • no access to a working phone

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Boston Medical Center

    Boston, Massachusetts, 02118

Other trials in United States

About this study

The purpose is to analyze whether a follow-up telephone call by a pharmacist after patient discharge from the hospital can improve patient outcomes.

Patients will be interviewed via telephone within 72 hours of being discharged home from the hospital. Patients will be questioned on three main topics. They are:

Read more
  1. Medical care
  2. Medications
  3. Follow-up appointments

The purpose is to find out if people understand discharge medications, have obtained those medications, are having any problems with their medications and have scheduled necessary follow-up appointments. It will be determined if a telephone call by a pharmacist will prevent patients from needing to go to the Emergency Room or being admitted back to the hospital.

Read the detailed description

There is a time between hospital discharge and patient follow-up that has been deemed by many healthcare workers as a "black hole " (1). It is a time during which continuity of care is of utmost importance, yet there is no effective uniform system in place to ensure this vital continuity. During the post-discharge period (time from when the patient leaves the hospital to the time of first follow-up appointment), new medical problems can arise and old ones can be exacerbated. Additionally, patients can encounter innumerable barriers to healthcare, including difficulty obtaining medications and securing appointments with physicians or specialists. Also, patients may not have received proper counseling on new discharge medications, including proper use and potential side effects. Despite this important aspect of patient care, only a paucity of literature on the topic exists. Of the literature that does exist, it suggests that patient education concerning discharge planning and the post-discharge period is an aspect of care that is in great need of improvement and an excellent opportunity for intervention by a pharmacist.

This led to our research hypothesis, can a follow-up phone call from a pharmacist improve patient outcomes?

The primary endpoint of this study is a reduction in the number of hospital readmissions (any cause) during the 30-day post-discharge period. Thirty-day readmission rates will be compared to see if there is a difference between the intervention group (follow-up phone call) and control group (no phone call). The secondary outcomes include the number of patients in the study group for whom medication errors, complications or misuse could be identified.

References: (1). Kathuria, et al. Post-discharge follow-up: hospitalists dial into the "black hole". Hospitalist and Inpatient Management Report, June 2003

Being tested
telephone call by a pharmacist
Keywords
pharmacist intervention, post-discharge telephone call, black hole

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • telephone call by a pharmacistBehavioural

Study groups in NCT00332514
Study groupRoleWhat they receive
Patients offered follow-up phone callOtherPatients offered follow-up telephone call
Receives: Behavioral: telephone call by a pharmacist

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The primary endpoint of this study is a reduction in the number of hospital readmissions (any cause) during the 30-day post-discharge period.

Secondary outcomes (1)
  1. The secondary outcomes include the number of patients in the study group for whom medication errors, complications or misuse could be identified.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jun 2006 (estimated)
  2. Study startMar 2004
  3. Primary completionJan 2008
  4. Study completionJan 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants
IDs, dates and publications
ClinicalTrials.gov ID
NCT00332514
Sponsor's protocol ID
H-23071
Status last verified
Mar 2006
First submitted
31 May 2006
Last updated
23 Feb 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing telephone call by a pharmacist in people with Readmission, Hospital, run by Boston Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Feb 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The primary endpoint of this study is a reduction in the number of hospital readmissions (any cause) during the 30-day post-discharge period.. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in